Attivare Therapeutics, a Harvard startup out of the Wyss Institute, has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS), Dana-Farber Cancer Institute, and Massachusetts General Hospital. This technology creates an in vivo training ground for the immune system to fight cancer more effectively and prevent infection.

The Wyss Institute at Harvard University announced that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard’s Office of Technology Development (OTD) and Boston University (BU)’s Technology Development office for novel molecules that activate the lymphatic system.

Circe, a Harvard startup, will commercialize a novel bioproduction technology that could significantly reduce the carbon emissions of industries from food to aviation fuel. To start, the team is using their triglycerides to make the world’s first gas fermentation-derived chocolate.

Researchers develop a compact, single-shot, and complete polarization imaging system using metasurfaces.